AI assistant
HAEMONETICS CORP — Director's Dealing 2010
Jul 30, 2010
31565_dirs_2010-07-30_e25580c2-6d0b-44ad-b0d6-105239854d18.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2010-07-28
Reporting Person: Kelly Michael P (President, NA, Global Plasma)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2010-07-28 | Common Stock | A | 2183 | $54.97 | Acquired | 2183 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2010-07-28 | Non-Qualified Stock Option (right to buy) | $54.97 | A | 31270 | Acquired | 2017-07-28 | Common Stock (31270) | Direct |
Footnotes
F1: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.